Veronica (Novotny) Diermayr; PhD
Head of Development at D3 (Drug Discovery and Development), BMSI
LINKS
Studied at Universität Wien
Past: Goethegymnasium
Summary
* Broad understanding of cancer biology, holistically applied to the discovery and development of drugs and biomarkers.
Experienced in preclinical and early clinical development in oncology & infectious diseases and immunology for small molecule and biologics
* Proven ability to contribute to preclinical and Phase 1/2 development, biomarker development and validation, medical rationale & positioning, study protocol development and Investigator's Brochure writing
* Excellent scientific, leadership, personal management and organizational skills
* Knowledgeable and trained in GLP and GCP and a very keen interest in the medical aspects of oncology and immunology
* Keen, enthusiasticand emphathetic team worker with a “can-do” attitude, good mentoring skills and proven leadership qualities
Specialties: Key areas of expertise: biomarker development, pre-clinical and early clinical development (Phase 0 – 2) in the areas of oncology, immunology, infectious diseases; in-depth and hands-on knowledge of animal efficacy studies, pharmacodynamics and PK/PD models, in vitro kinase assays, molecular biology, signal transduction, protein production, clinical research, project management, scientific writing
Experienced in preclinical and early clinical development in oncology & infectious diseases and immunology for small molecule and biologics
* Proven ability to contribute to preclinical and Phase 1/2 development, biomarker development and validation, medical rationale & positioning, study protocol development and Investigator's Brochure writing
* Excellent scientific, leadership, personal management and organizational skills
* Knowledgeable and trained in GLP and GCP and a very keen interest in the medical aspects of oncology and immunology
* Keen, enthusiasticand emphathetic team worker with a “can-do” attitude, good mentoring skills and proven leadership qualities
Specialties: Key areas of expertise: biomarker development, pre-clinical and early clinical development (Phase 0 – 2) in the areas of oncology, immunology, infectious diseases; in-depth and hands-on knowledge of animal efficacy studies, pharmacodynamics and PK/PD models, in vitro kinase assays, molecular biology, signal transduction, protein production, clinical research, project management, scientific writing
Experience
Head of Project Management
D3 (Drug Discovery and Development), BMSI
As
a Project Manager and biomarker expert in D3 we are currently doing the
pre-clinical development of an anti-neoplastic small molecule (wnt
signaling inhibitor) for solid tumors targeting to obtain an IND by
Sept. 2014.
We have successfully completed the a Phase I, first-in man, healthy volunteer, multi-center study testing a VLP-vaccine.
Our small- molecule kinase inhibitors for the treatment of a subset of chronic myeloid leukemia patients are just entering preclinical development. Furthermore D3 is in the process of in-licensing two exciting first-in class oncology compounds.
In the non-oncology area we are involved in the preclinical development of MSC exosomes for small indications for PoC.
We have successfully completed the a Phase I, first-in man, healthy volunteer, multi-center study testing a VLP-vaccine.
Our small- molecule kinase inhibitors for the treatment of a subset of chronic myeloid leukemia patients are just entering preclinical development. Furthermore D3 is in the process of in-licensing two exciting first-in class oncology compounds.
In the non-oncology area we are involved in the preclinical development of MSC exosomes for small indications for PoC.
Team Leader
S*BIO Pte Ltd
- Project management & leadership for biomarker group and animal pharmacology group
- Biology leader for an early stage drug discovery project
- Coordinate research with other teams
- Manage CROs for various outsourced studies
- Coordinate work with clinical study teams to validate and apply biomarkers for clinical trials
- Operationally support the application of validated biomarkers for clinical trials
- Organize, report and communicate study outcome to the project team
- Write & submit scientific publications as corresponding author
- Deliver & present data packages & scientific rationale for filings (IND, FDA, reports etc)
- present to senior management/international community
- perform as an effective leader who supervises and coaches research associates
- Biology leader for an early stage drug discovery project
- Coordinate research with other teams
- Manage CROs for various outsourced studies
- Coordinate work with clinical study teams to validate and apply biomarkers for clinical trials
- Operationally support the application of validated biomarkers for clinical trials
- Organize, report and communicate study outcome to the project team
- Write & submit scientific publications as corresponding author
- Deliver & present data packages & scientific rationale for filings (IND, FDA, reports etc)
- present to senior management/international community
- perform as an effective leader who supervises and coaches research associates
Senior Reserach Fellow
Institute for Molecular and Cell Biology (IMCB), Singapore
Molecular Biology studies in the field of Oncology
Research Fellow
Novartis Research Institute, Vienna, Austria
Mast Cells & Dendritic cells, Sphingosine Kinase pathways, compound screening for novel inhibitors
- (Open)1 organization
Research fellow, Vienna Medical University, Institute of Immunology
VIRC - Vienna International Reserach Cooperation, Institute of Immunology (Prof. Knapp)
studied the active signal transduction pathways in patients with Wiskott-Aldrich Syndrome using EBV transformed B-cells
Certifications
Organizations
Publications
Phase 1 and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939,in patients with refractory solid malignancies
Annals of Oncology
March 8, 2011Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of SB939, an Oral Histone Deacetylase Inhibitor (HDACi), in Patients with Advanced Solid Tumors
British Journal of Cancer
February 1, 2011SB939, a novel potent and orally active histone deacetylase inhibitor with high exposure and efficacy in mouse models of colorectal cancer
Molecular Cancer Therapeutics
March 2, 2010Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia(Link)
Blood Cancer J
November 1, 2011VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer(Link)
Molecular Cancer Therapeutics
December 27, 2012- 2 authors
Veronica Diermayr; PhD
Head of Development at D3 (Drug Discovery and Development), BMSI
Stefan Hart
Director, New Ventures Singapore/SEA/India at Johnson & Johnson Innovation Center Asia Pacific
Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction
Journal of Biological Chemistry
January 27, 2005The LIM/homeodomain protein Islet1 recruits Janus tyrosine kinases and signal transducer and activator of transcription 3 and stimulates their activities
Molecular Biology of the Cell
January 19, 2005A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation
The Journal of Biological Chemistry
May 13, 2003GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction
EMBO J.
March 17, 2003Protein kinase C associates with the interleukin-6 receptor subunit gp130 via Stat3 and enhances Stat3-gp130 interaction
Journal of Biological Chemistry
2002Novel mode of interference with NF-AT regulation in T-cells by the bacterial metabolite n-butyrate
Journal of Biological Chemistry
2002Glycosphingolipid-induced relocation of Lyn and Syk into detergent resistant membranes results in mast cell activation
Journal of Immunology
2000The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after FcRI triggering
The Journal of Experimental Medicine
1999TNF and IL-5 gene induction in IgE plus antigen stimulated mast cells require common and distinct signaling pathways
International Archives of Allergy and Immunology
1999Nrf1 in a complex with fos B, c-jun, junD, and ATF2 forms the AP1 component at the TNF promoter in stimulated mast cells.
Nucleic Acid Research
1998Common and distinct signaling pathways mediate the induction of TNF and IL-5 in IgE plus antigen-stimulated mast cells
The Journal of Immunology
1998A novel splice variant of the transcription factor Nrf1 interacts with the TNF promoter and stimulates transcription
Nucleic Acid Research
1998The ultrastructure of the cuticle of Nematoda II. The cephalic cuticle of Stilbonematinae (Adenophoraea, Desmodoridae)
Zoomorphology
1996Education
Medizinische Universität Wien
Ph.D.,, Immunology (Prof. Knapp)
Lectures in immunology, FACS analyses, focus on hematology-oncology,
Activities and Societies: Austrian Society of Haematology
////////
.
